Every material Form 8-K Journey Medical Corp has filed with the SEC since April 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Journey Medical reported second-quarter 2026 revenue of $18.5 million, up 23% from $15.0 million a year earlier, with Emrosi contributing $8.1 million. The GAAP net loss narrowed to $0.3 million, or $0.01 per share, from $3.8 million, or $0.16 per share, in the prior-year quarter. The filing gives no financial guidance, and the company reported $25.6 million in cash at June 30, 2026.
Total revenue of $18.5 million for the quarter ended June 30, 2026, up 23% from $15.0 million
Emrosi revenue of $8.1 million in the quarter; total prescriptions were approximately 36,000, up from approximately 30,000 in the first quarter of 2026
GAAP net loss of $0.3 million, or $(0.01) per share, versus $3.8 million, or $(0.16) per share, a year earlier
Cash and cash equivalents of $25.6 million at June 30, 2026; gross margin was 67%, consistent with the prior-year quarter
Journey Medical reported first-quarter 2026 results for the three months ended March 31, 2026. Total revenue rose 21% to $16.0 million and the net loss narrowed to $2.2 million, or $(0.08) per share, from $4.1 million, or $(0.18) per share, a year earlier. Gross margin fell to 61.0% because of a $1.3 million non-cash inventory write-down tied to a 2021 Qbrexza asset acquisition.
Total revenue was $16.0 million, up from $13.1 million in the first quarter of 2025.
Emrosi revenue was $6.3 million, compared with $2.1 million a year earlier.
Gross margin decreased to 61.0% from 63.5%, mainly due to a $1.3 million non-recurring non-cash charge.
Cash and cash equivalents were $27.2 million at March 31, 2026, up from $24.1 million at December 31, 2025.
On April 21, 2026, Journey Medical Corporation said about 85% of US commercial lives now have access to Emrosi, its rosacea treatment, after contracting with a third major group purchasing organization. The company said commercial-life access rose from about 100 million to over 150 million as of April 1, 2026. Management expects wider coverage to support further prescription demand and, over time, less reliance on its co-pay bridging program and better brand profitability, but the filing reports no financial results.
Emrosi access now covers about 85% of US commercial lives after a contract with the third major GPO
Commercial lives with access rose from about 100 million to over 150 million as of April 1, 2026
Management expects less reliance on the co-pay bridging program and improved brand profitability as formulary adoption grows
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Journey Medical Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →